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Abstract: Continuous glucose monitoring (CGM) devices, with their 1-5 minute measurement interval, allow 
blood glucose dynamics to be captured more frequently and less invasively than traditional measures of 
blood glucose concentration (BG). These devices are primarily designed for the use in type 1 and type 2 
diabetic patients to aid BG regulation. However, because of their increased measurement frequency and 
reduced invasiveness CGM devices have been recently applied to other subject cohorts, such as intensive 
care patients and neonates. One unexamined cohort is athletes. Continuous monitoring of an athlete’s BG 
has the potential to increase race performance, speed recovery, and aid training, as BG can reflect metabolic 
and inflammatory conditions. However, before these benefits can be realized the accuracy and performance 
of CGM devices in active athletes must be evaluated. 
 
Two Ipro2 CGM devices (Medtronic Minimed, Northridge, CA, USA) were inserted into an athlete (resting 
HR 50 beats per minute (bpm), training 10-17hrs per week). Two fasting exercise tests were carried out 3 
days apart, involving 2 hours of continuous exercise and a glucose bolus at the end of the 2 hours. Reference 
BG measurements were taken regularly. These tests were then repeated while the athlete was sedentary, HR 
< 80bmp.  CGM devices agree well with each other and reference measurements during rigorous exercise 
with a median [IQR] MARD of 7.3 [5.4 – 10.9] %. During sedentary periods the accuracy of the CGM trace 
compared to reference measurements was reduced, 25.1 [16.9 35.4] %. However the good agreement 
between the sensors is maintained. This decrease in accuracy is likely related to the fact interstitial fluid is 
not actively pumped like blood. It relies on muscle movement to circulate and mix. Thus, it can be expected 
that during exercise more accurate results are seen as the rigorous movement allows rapid mixing and 
equilibrium between the blood and interstitial fluid. 

1. INTRODUCTION 
Continuous glucose monitoring (CGM) devices, with their 1-
5 minute measurement interval, allow blood glucose 
concentration (BG) dynamics to be captured more frequently 
and less invasively than traditional measures of BG. CGM 
devices typically consist of a small pager-like monitoring 
device that receives a signal from a sensor inserted into the 
subcutaneous layer. The sensor creates a signal using the 
glucose oxidase reaction and produces a current which is 
proportional to the glucose concentration in the interstitial 
fluid. Calibration algorithms convert the signal into a BG by 
comparing it to known calibration BG measurements, which 
are entered into the monitor by the user every ~6-8hrs. 
These devices are primarily designed for the use in type 1 and 
type 2 diabetic patients to aid BG regulation and are well 
studied in this cohort (Gandhi et al., 2011, Hoeks et al., 2011). 
However, because of the increased measurement frequency 
and reduced invasiveness they have recently been applied to 
other cohorts, such as intensive care patients and neonates with 
varying success (Chee et al., 2003, Holzinger et al., 2010, 
Brunner et al., 2011, Rabiee et al., 2009, Signal, 2013, Signal 
et al., 2010, Beardsall et al., 2005, Harris et al., 2010).  
One unexamined cohort is athletes. Optimisation of an 
athlete’s BG  has the potential to increase race performance, 
speed recovery, and aid training (Jeukendrup, 2004, Achten et 
al., 2004, Koopman et al., 2004, Halson et al., 2004, Brown, 
2002).  However, before these benefits can be realised, the 
accuracy and performance of CGM devices in active athletes 
must be evaluated. Hence, this paper compares the accuracy 
and performance of CGM in an athlete while exercising and 
sedentary.   
 
2. SUBJECTS & METHODS 
2.1 Subjects and Experiments  
Two Ipro2 CGM devices (Medtronic Minimed, Northridge, 
CA, USA) were inserted into the abdomen of an athlete 
(Female, 23yrs, BMI 21kg/m2, resting HR 50 beats per minute 
(bpm), training 10-17hr per week) at least a day prior to the 
first ‘fasting exercise test’.  
During the 5 days of CGM:  
• Blood glucose was measured 4 times a day prior to 
meals and sleeping. These measurements were used 
to calibrate the device (calibration BGs)   
• All meals were recorded and carbohydrate intake 
monitored.  
  
     
 
• Any additional exercise was also recorded and energy 
expended estimated  
Two fasting exercise tests were carried out 3 days apart: 
• 0-60min: Cycling on a stationary trainer after 
overnight fasting in the submaximal endurance HR 
zone (130-140bpm) 
• 60-120min: Steadily increase HR until exhaustion 
(190bpm)  
• 120min: Consume a 1g/kg of body weight(60g) 
glucose drink  
• The athlete was required to take a rest day prior to the 
first fasting test.  
Reference BG measurements were taken: 
• Every 10min during the 2hrs of exercising,  
• every 5min for 30 minutes after the glucose solution 
was ingested  
• One final measurement was taken 40min after the 
glucose solution was ingested  
Reference measurements were not used for calibration.   
At a later date, two Ipro2 CGM devices were inserted into the 
same athlete the day prior to the first ‘fasting sedentary test’. 
The same procedure was followed during the 6 days of CGM 
and during the tests except the athlete remained sedentary for 
the same 120min period of regular reference blood glucose 
measurements. A glucose solution of 60g was consumed at 
120min, and further BG measures made as per the exercise 
tests. The athletes HR during this time was >80bpm.  
Reference and calibration BG measurements were taken using 
capillary finger stick measurements and the Abbott Optimum 
Xceed (Abbott Diabetes Care, Alameda, CA) glucometer. The 
Abbott device has reported error of 5-10% (Abbott, 2010, 
Thomas et al., 2014b, Thomas et al., 2014a, Signal, 2013). For 
both tests the same CGM devices were used and inserted in to 
the left side of the abdomen. These devices are referred to as 
sensor 1, the lower left abdomen sensor, and sensor 2, the 
upper left abdomen sensor.  
 
2.2 Analysis  
To assess the accuracy of the CGM during exercise the mean 
absolute relative difference (MARD) was calculated between 
reference BG measurements collected during the fasting tests 
and the CGM trace:  
               𝑀𝐴𝑅𝐷 = 𝑚𝑒𝑎𝑛(𝑎𝑏𝑠 (
𝐶𝐺𝑀−𝐵𝐺
𝐵𝐺
)) ∗ 100         Eq 1. 
MARDs were assessed during the exercise or sedentary phase 
only, and including the glucose bolus subsequent to these 
phases. This consideration of different phases allowed an 
assessment of accuracy when glucose levels were rapidly 
changing, after the glucose bolus, and when they are relatively 
stable, during exercise or while sedentary. The sedentary and 
exercise test thus provide equivalent samples in two distinct 
states.   
The offset of the CGM trace compared to the reference BG 
measurements was also analysed for these different phases. 
This offset was calculated: 
                          𝑂𝑓𝑓𝑠𝑒𝑡 = 𝐶𝐺𝑀 − 𝐵𝐺              Eq 2. 
Where, a positive offset means the CGM reading was higher 
than the reference BG.  
It was also noted that while the sensor current (ISIG) captured 
by the two different CGM devices were very similar (panel A 
of Figure 1) there was some discrepancy between the BG 
traces produced by the factory calibration algorithm (panel B 
of Figure 1). Therefore, an alternative recalibration method 
was employed (panel C of Figure 1) (Signal et al., 2012). The 
recalibration algorithm forces the output CGM trace to pass 
through the calibration BG measurements, while preserving 
the raw sensor current. At each calibration measurement a 
value of slope is calculated. Linear interpolation of the 
required slope gives the new, continuous slope function. This 
slope is used with the unmodified ISIG to generate the 
recalibrated BG trace. The recalibration provides a comparator 
to assess the impact of the factory calibration, which is not 
specifically designed for athletes, on outcome CGM traces. 
 
3. RESULTS & DISCUSSION 
The results in Figure 1, Figure 3 and Table 1 clearly show 
CGM devices are accurate during intense exercise. The 
MARD values in Table 1 are equivalent if not better than the 
performance reported for CGM in diabetic subjects (Keenan et 
al., 2012, Kovatchev et al., 2008, Bailey et al., 2014, 
Matuleviciene et al., 2014, Calhoun et al., 2013). Bailey et al. 
reported an overall MARD of 13.6% from a study using the 
same sensors in 90 type 1 diabetic subjects. All of the 
recalibrated MARD values are below this value with a range 
of 6.6-12.9%, and only two of the factory calibrated MARD 
values are above with a range of 8.6-17.9%.  
The recalibration algorithm improves performance with the 
median MARD of the recalibrated trace being 8.7% during 
exercise and the following glucose bolus compared to 11.4% 
for the factory calibrated CGM trace. The recalibration allows 
the CGM signal to better capture the fast changing glucose 
dynamics induced with the glucose bolus consumed at 
120min, as seen in Figure 3.  
Most athletes are highly motivated individuals with a high 
attention to detail and procedure. However, a number of the 
diabetic individuals this CGM device is designed for may not 
have the same motivation for monitoring BG and will be 
relying on infrequent and poorer quality BG measurements. 
Hence, the factory calibration algorithm weights each BG 
value differently based on how accurate it assesses the BG 
measurement to be. This weighting leads to the discrepancies 
between the two signals seen in Figure 1 at 1000, 5000 and 
6000 minutes, where the algorithm has treated the calibration 
BGs differently for each sensor.  
The overall performance of the CGM devices during the 
sedentary test in Figure 2 is also very good. Both sensor 
current and output CGM trace from the two sensors agree well. 
However, the performance during the sedentary tests alone 
  
     
 
was not as accurate as during the exercise tests. In Figure 4, 
there is a noticeable offset between the reference 
measurements and the sensor output. This difference is also 
highlighted in Table 2 where the median offset is up to 
1.9mmol/L during the second test.   
Comparing the recalibrated results, as they provided the most 
accurate results, the Median [IQR] MARD during exercise test 
and glucose was 8.7 [7.2 – 12.2] % compared to 26.4 [17.6 
35.2] % during the sedentary test. These results only improve 
by ~1% when the glucose bolus period was removed from the 
analysis to 7.3 [5.4 – 10.9] % and   25.1 [16.9 35.4] % 
respectively. Thus, the CGM signals were both able to track 
the fast changing glucose dynamics nearly accurately as they 
were the relatively constant BG during the exercise or 
sedentary phase. Hence, the difference between the two tests 
is due to other factors.   
The large discrepancy seen between the accuracy of the 
devices while exercising compared to being sedentary is 
attributed to two main factors. First, the reference 
measurements may have been biased during the sedentary test. 
During this test the apparent skin temperature was noticeably 
lower than in the exercise tests and it was more difficult to 
extract blood from the finger tips indicating reduced 
circulation(Thorsson et al., 1985, Gregson et al., 2011). There 
is evidence to suggest lower skin temperatures lead to BG 
meters reading lower than expected values (Haupt et al., 2005, 
King et al., 1995). Second, interstitial fluid is not actively 
pumped like blood. It relies on muscle movement to circulate 
and mix. Thus, it can be expected that during exercise more 
accurate results are seen as the rigorous movement allows 
rapid mixing and equilibrium between the blood and 
interstitial fluid as well as more accurate reference BG 
measurements due to high skin temperatures and increased 
circulation.  
There is a consistent positive bias evident in Table 2, whether 
it be exercising or sedentary, or when applying the 
recalibration algorithm or the factory algorithm. While it 
changes in size depending on the accuracy of the signal, the 
consistently positive offset would suggest that the CGM is 
likely to be reading higher that the BG actual is. This could 
have important implications for athletes using these devices as 
if they were using the CGM device and the factory algorithm 
to guide nutrition during exercise. The CGM value could be 
between 0.4 – 0.8mmol/L higher than their measured BG. 
Finger stick measurements may also contribute to this bias if 
they are in accurate. Future studies with larger cohorts will 
help better quantify this bias and the causes of it. Then, if 
necessary, a factor could be applied in calibration to remove 
its influence.    
     
Figure 1: Exercise Test: Sensor current generated by each 
sensor during the 5 days of CGM that the fasting exercise tests 
were conducted during, (A), the CGM signal produced by 
using the factory calibration, (B), the CGM signal produced 
when the recalibration algorithm was applied (C).     
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Figure 2: Sedentary Test: Sensor current generated by each 
sensor during the 6 days of CGM that the sedentary tests were 
conducted during, (A), the CGM signal produced by using the 
factory calibration, (B),the CGM signal produced when the 
recalibration algorithm was applied (C).     
 
 
Figure 3: CGM data and the recalibrated trace for each 
exercise test and the reference BG measurements taken.  
 
Table 1: MARDs from tests, including and excluding the 
glucose bolus and comparing the recalibration data and the 
original CGM algorithm. The recalibration algorithm has 
lower MARDs for both during exercise and when glucose 
levels a rapidly changing post exercise.  
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7.07 10.1 7.37 12.9 8.74 [7.15 12.2]
MARD (%) 
exercise Only 




8.55 12.6 10.1 16.9 11.4 [8.9 15.8]
MARD (%) 
exercise Only 
8.73 12.9 8.67 17.9 10.8 [8.69 16.7]




18.6 17.8 35.9 34.9 26.4 [17.6 35.2]
MARD (%) 
exercise Only 




22.4 18.8 40.8 37.6 30 [21.5 38.4]
MARD (%) 
exercise Only 






































     
 
 
Figure 4: CGM data and the recalibrated trace for each 
sedentary test and the reference BG measurements taken.  
 
Table 2: Offsets from tests, including and excluding the 
glucose bolus calculated as per Eq 2. CGM trace is consistently 
higher than the reference blood glucose measurements 




3.1 Limitations  
The recalibration method used was designed for use with blood 
gas analyser (BGA) measurements. BGA’s are accurate to 
within 2% are considered the ‘gold standard’ for hospital BG 
measurements. The reference and calibration measurement for 
this study were recorded on an Abbott Optimum Xcceed with 
reported a reported error range of 5-10% (Abbott, 2010, 
Signal, 2013, Thomas et al., 2014a, Thomas et al., 2014b), as 
mentioned earlier. Hence, forcing the CGM trace through 
these less precise measurements may induce additional error 
in to the recalibrated trace. However, the improvement seen 
from recalibration with the better agreement of the two signals 
and improved MARD justifies this additional error. The details 
of the manufacture algorithms are not fully disclosed. 
Therefore it was not possible to use one directly in this study 
and optimise it for athletes.   
This study is a proof of concept demonstration. The small data 
set is a limitation of this study. These tests were only trialled 
in one athlete and results are likely to vary between 
individuals. However, there is a clear difference in signal 
quality between exercising and sedentary cases. These 
differences also provide insight into how these devices might 
be more optimally used in the target, more sedentary cohort. 
Finally, the results justify investment in further, ongoing tests 
in athletic subjects.  
 
4. CONCLUSION 
Optimisation of an athlete’s BG has the potential to increase 
race performance, speed recovery and aid training. CGM 
devices agree well with each other and reference 
measurements during rigorous exercise with a MARD of 10.8 
[8.7 – 16.7] % median [IQR]. However, a different calibration 
algorithm to that provided by the manufacture maybe more 
suited to this cohort, 7.3 [5.4 – 10.9] %. During sedentary 
periods the accuracy of the monitors was reduced, 25.1 [16.9 
35.4] %, however the good agreement between the sensors is 
maintained. This decrease in accuracy is likely related to the 
fact interstitial fluid is not actively pumped like blood. It relies 
on muscle movement to circulate and mix. Thus, it can be 
expected that during exercise more accurate results are seen as 
the rigorous movement allows rapid mixing and equilibrium 
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